Generation Bio (NASDAQ: GBIO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.610 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Generation Bio (NASDAQ: GBIO) through any online brokerage.
Other companies in Generation Bio’s space includes: Innate Pharma (NASDAQ:IPHA), Kezar Life Sciences (NASDAQ:KZR), Precigen (NASDAQ:PGEN), 4D Molecular Therapeutics (NASDAQ:FDMT) and Burning Rock Biotech (NASDAQ:BNR).
The latest price target for Generation Bio (NASDAQ: GBIO) was reported by JMP Securities on Wednesday, December 15, 2021. The analyst firm set a price target for 10.00 expecting GBIO to rise to within 12 months (a possible 84.50% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Generation Bio (NASDAQ: GBIO) is $5.42 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Generation Bio.
Generation Bio’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Generation Bio.
Generation Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.